Literature DB >> 9281508

Characterization of an overlapping CD8+ and CD4+ T-cell epitope on rubella capsid protein.

D Ou1, L A Mitchell, D Décarie, S Gillam, A J Tingle.   

Abstract

A synthetic peptide corresponding to rubella virus capsid protein residues 263 to 275 which contains an epitope recognized by a cloned CD4+ cytotoxic T-lymphocyte (CTL) line was used to induce CD8+ T-cell lines specific to this peptide. A peptide-specific CD8+ CTL clone was derived and characterized. This peptide-specific CD8+ CTL clone exhibited cytotoxicity against target cells infected by a vaccinia recombinant virus expressing rubella virus capsid protein, but not by target cells infected by vaccinia recombinant virus expressing rubella virus E1 or E2 envelope proteins. Analysis of HLA class I restriction of the CD8+ CTL clone revealed that A11 and A3 were restrictive elements. Fine mapping with truncated and overlapping peptide analogs revealed a nonamer sequence, C(264-272), as the T-cell epitope eliciting stronger cytotoxicity. Two anchor residues for binding to HLA A11 and A3 were identified at position 2 (isoleucine) and at position 9 (histidine) or at position 8 (arginine) of the epitope sequence. The identification of overlapping CD4+ and CD8+ T-cell epitopes within the capsid protein sequence C(263-275) implicates a strategy for using such epitopes in a candidate peptide-based rubella vaccine.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9281508     DOI: 10.1006/viro.1997.8704

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  7 in total

1.  Regulation of CD4 T cells and their effects on immunopathological inflammation following viral infection.

Authors:  Mitra Bhattacharyya; Patrick Madden; Nathan Henning; Shana Gregory; Malika Aid; Amanda J Martinot; Dan H Barouch; Pablo Penaloza-MacMaster
Journal:  Immunology       Date:  2017-07-14       Impact factor: 7.397

2.  Induction of a cross-reactive CD8(+) T cell response following foot-and-mouth disease virus vaccination.

Authors:  Efrain Guzman; Geraldine Taylor; Bryan Charleston; Shirley A Ellis
Journal:  J Virol       Date:  2010-09-22       Impact factor: 5.103

3.  Vaccine-elicited CD4 T cells induce immunopathology after chronic LCMV infection.

Authors:  Pablo Penaloza-MacMaster; Daniel L Barber; E John Wherry; Nicholas M Provine; Jeffrey E Teigler; Lily Parenteau; Stephen Blackmore; Erica N Borducchi; Rafael A Larocca; Kathleen B Yates; Hao Shen; W Nicholas Haining; Rami Sommerstein; Daniel D Pinschewer; Rafi Ahmed; Dan H Barouch
Journal:  Science       Date:  2015-01-16       Impact factor: 47.728

4.  Correlation between rubella antibody levels and cytokine measures of cell-mediated immunity.

Authors:  Pritish K Tosh; Richard B Kennedy; Robert A Vierkant; Robert M Jacobson; Gregory A Poland
Journal:  Viral Immunol       Date:  2009-12       Impact factor: 2.257

5.  Extended LTA, TNF, LST1 and HLA gene haplotypes and their association with rubella vaccine-induced immunity.

Authors:  Inna G Ovsyannikova; Robert A Vierkant; V Shane Pankratz; Robert M Jacobson; Gregory A Poland
Journal:  PLoS One       Date:  2010-07-27       Impact factor: 3.240

6.  Highly conserved cross-reactive CD4+ T-cell HA-epitopes of seasonal and the 2009 pandemic influenza viruses.

Authors:  Venkata R S K Duvvuri; Seyed M Moghadas; Hongbin Guo; Bhargavi Duvvuri; Jane M Heffernan; David N Fisman; Gillian E Wu; Jianhong Wu
Journal:  Influenza Other Respir Viruses       Date:  2010-09       Impact factor: 4.380

7.  Infectious vaccine-derived rubella viruses emerge, persist, and evolve in cutaneous granulomas of children with primary immunodeficiencies.

Authors:  Ludmila Perelygina; Min-Hsin Chen; Suganthi Suppiah; Adebola Adebayo; Emily Abernathy; Morna Dorsey; Lionel Bercovitch; Kenneth Paris; Kevin P White; Alfons Krol; Julie Dhossche; Ivan Y Torshin; Natalie Saini; Leszek J Klimczak; Dmitry A Gordenin; Andrey Zharkikh; Stanley Plotkin; Kathleen E Sullivan; Joseph Icenogle
Journal:  PLoS Pathog       Date:  2019-10-28       Impact factor: 6.823

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.